JAK inhibition in IMIDs: Where are we now?
Review the current and future therapeutic landscape of RA, PsA, and axSpA.
Chairs: Lai-Shan Tam and Iain McInnes
JAK inhibitors in RA – where do they fit in the treatment paradigm?
The therapeutic landscape of PsA treatment
Latest overview of the management of axSpA
Q&A and close
Review on ILDs: Diagnosis and risk factors
Rheumatologist perspectives – Screening, symptoms assessment and risk factors
Prof Anna Hoffman-Vold
Pulmonary perspectives – importance of lung function test and co management
Prof Michael Kreuter
Radiologist perspectives – HRCT and differential diagnosis
Prof Joseph Jacob